Skip to content
Clinical Trials – home
Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study aims to compare the effectiveness of a new treatment called teclistamab with other existing treatments. These existing treatments include combinations of medications such as pomalidomide, bortezomib, and dexamethasone, as well as carfilzomib and dexamethasone. Pomalidomide is also known by its code name CC-4047, and carfilzomib is sometimes referred to as PR-171. The study will also involve a placebo group for comparison.

The purpose of the study is to determine which treatment is more effective for patients with relapsed or refractory multiple myeloma, meaning the cancer has returned or is not responding to previous treatments. Participants in the study will receive one of the treatments mentioned above, and their progress will be monitored over time. The study will help researchers understand how well these treatments work in managing the disease and improving patient outcomes.

Participants will be randomly assigned to receive either the new treatment or one of the existing treatment combinations. The study will take place over a period of time, during which participants will be regularly assessed to track their response to the treatment. The main goal is to see how long patients can live without the disease getting worse, known as progression-free survival. This study is an important step in finding better ways to treat multiple myeloma and improve the quality of life for those affected by this condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of multiple myeloma and ensuring previous treatments align with study requirements.

  2. Step 2

    Randomization

    Participants are randomly assigned to one of two groups: one receiving teclistamab alone, and the other receiving a combination of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd).

  3. Step 3

    Treatment phase

    For those in the teclistamab group, the medication is administered via subcutaneous injection. The frequency and dosage are determined by the study protocol.

    Participants in the PVd group receive pomalidomide orally in capsule form, bortezomib as a subcutaneous injection, and dexamethasone orally in tablet form. Dosages and schedules are specified in the study protocol.

    Participants in the Kd group receive carfilzomib as an infusion and dexamethasone orally. The dosage and frequency are outlined in the study protocol.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess the effectiveness of the treatment and to check for any side effects. This includes blood tests and other necessary evaluations.

    Follow-up visits are scheduled according to the study timeline to ensure ongoing assessment of health status and treatment response.

  5. Step 5

    Completion of study

    The study is estimated to conclude by December 19, 2030. Participants will have a final assessment to evaluate the overall outcomes of the treatment received.

Who can join the trial?

7 criteria

  • Must have a documented diagnosis of multiple myeloma, which is a type of blood cancer.
  • Must have a measurable disease at screening, which means certain levels of specific proteins in the blood or urine are present.
  • Must have received 1 to 3 previous treatments for multiple myeloma, including specific medications like an anti-CD38 monoclonal antibody and lenalidomide.
  • Must show evidence that the disease is getting worse or that the last treatment did not work, as determined by a doctor.
  • Must have an ECOG performance status score of 0 to 2, which is a scale used to assess how well a person can perform daily activities.
  • If female, must agree not to be pregnant, breastfeeding, or planning to become pregnant during the study and for 6 months after the last treatment.
  • Must be willing and able to follow the lifestyle restrictions required by the study.

Who cannot join the trial?

5 criteria

  • Patients who have a different type of cancer other than relapsed/refractory multiple myeloma. This means the cancer has returned or is not responding to treatment.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specified clinical trial groups.
  • Patients who are not male or female, as the study includes both genders.
  • Patients who are considered part of a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Teclistamab

    is a medication being studied for its potential to treat multiple myeloma, a type of blood cancer. It is being tested to see how well it works on its own in patients who have already tried other treatments.

  • Pomalidomide

    is a medication used to treat multiple myeloma. It works by helping the immune system attack cancer cells and by stopping the growth of these cells.

  • Bortezomib

    is a medication that treats multiple myeloma by interfering with the growth of cancer cells, eventually destroying them. It is often used in combination with other medications.

  • Dexamethasone

    is a type of steroid that helps reduce inflammation and is used in combination with other medications to treat multiple myeloma. It can help improve the effectiveness of cancer treatments.

  • Carfilzomib

    is a medication used to treat multiple myeloma by blocking certain proteins in cancer cells, which leads to their death. It is often used when other treatments have not been successful.

What is already known about the treatment

  • Teclistamab

    Teclistamab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials for its effectiveness in treating relapsed or refractory multiple myeloma, a type of blood cancer. The medication works by targeting specific proteins on the surface of cancer cells, helping the immune system to recognize and destroy these cells. Teclistamab is classified as a monoclonal antibody, a type of drug designed to interact with specific targets in the body.

  • Pomalidomide

    Pomalidomide is taken orally in the form of capsules. It is an established treatment for multiple myeloma, particularly in patients who have not responded to other therapies. The drug works by modulating the immune system and inhibiting the growth of cancer cells. Pomalidomide belongs to a class of medications known as immunomodulatory agents.

  • Bortezomib

    Bortezomib is administered via injection, either under the skin or into a vein. It is widely used in the treatment of multiple myeloma and certain types of lymphoma. The medication functions by blocking the action of proteasomes, which are structures inside cells that break down proteins, leading to cancer cell death. Bortezomib is classified as a proteasome inhibitor.

  • Dexamethasone

    Dexamethasone is available in oral tablet form or as an injection. It is used in combination with other medications to treat multiple myeloma and other conditions. The drug works by reducing inflammation and suppressing the immune response. Dexamethasone is a corticosteroid, a type of steroid hormone.

  • Carfilzomib

    Carfilzomib is given as an injection into a vein. It is used for treating multiple myeloma, especially in patients who have not responded to other treatments. The drug acts by inhibiting proteasomes, leading to the accumulation of proteins in cancer cells and causing their death. Carfilzomib is also classified as a proteasome inhibitor.

Investigated diseases

Relapsed/Refractory Multiple Myeloma – This is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In relapsed multiple myeloma, the disease returns after a period of improvement. Refractory multiple myeloma refers to the condition not responding to treatment or stopping responding after a while. The disease can cause bone pain, anemia, kidney problems, and increased risk of infections. It progresses by causing abnormal plasma cells to multiply uncontrollably, leading to damage in bones and other organs. Over time, the accumulation of these cells can interfere with the production of normal blood cells.
Trial detailsLast updated 5 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2023-503444-13-00Protocol code64007957MMY3006Estimated enrolment590 patientsSponsorJanssen Cilag International

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.